Literature DB >> 12562545

Pharmacoeconomics of lipid-lowering drugs.

Dean G Smith1.   

Abstract

The widespread use and high cost of lipid-lowering drugs have resulted in numerous investigations of their cost effectiveness. Pharmacoeconomic analyses have considered initiation of treatment, maintenance therapy, and long-term outcomes of lipid-lowering therapy. Analyses have yielded a number of consistent messages, but the story continues to evolve as new trials, models, and drugs are introduced. Certain medications are more efficacious and associated with more cost-effective lipid-lowering therapy initiation. Other medications are lower priced and may be more cost effective for maintenance, contingent upon having achieved lipid-lowering goals. Finally, some medications have proven long-term cost effectiveness in trials and comparative cost effectiveness in models. Research is certain to further our understanding of the costs of lipid-lowering therapy and the methods needed to optimize expenditures.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562545     DOI: 10.1007/s11883-003-0070-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  48 in total

1.  Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.

Authors:  J J Caro; K F Huybrechts; G De Backer; D De Bacquer; M C Closon
Journal:  Acta Cardiol       Date:  2000-08       Impact factor: 1.718

2.  Managed care trends in statin usage.

Authors:  G R Bazalo
Journal:  Manag Care       Date:  2001-10

3.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

4.  The impact of the National Cholesterol Education Program Adult Treatment Panel III guidelines on drug development.

Authors:  Jonathan Isaacsohn; Donald Black; August Troendle; David Orloff
Journal:  Am J Cardiol       Date:  2002-03-07       Impact factor: 2.778

5.  Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.

Authors:  E Attanasio; P Russo; S E Allen
Journal:  Clin Ther       Date:  2001-02       Impact factor: 3.393

6.  Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Authors:  L A Prosser; A A Stinnett; P A Goldman; L W Williams; M G Hunink; L Goldman; M C Weinstein
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

7.  Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.

Authors:  D Black; M Davidson; M Koren; R Bakker-Arkema; P Tresh; R McLain; D Smith; D Hunninghake
Journal:  Pharmacoeconomics       Date:  1997-08       Impact factor: 4.981

8.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors.

Authors:  Karen A Grace; Jennifer Swiecki; Richard Hyatt; Henry Gibbs; David L Jones; Munazza Sheikh; John Spain; Kent W Maneval; Rebecca Viola; Allen J Taylor
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.